{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:27:26Z","timestamp":1773833246370,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis. AVF stenosis is a common complication, often requiring balloon angioplasty. For recurrent stenosis, AVF stenting may be an option. Persistent antiphospholipid antibody (aPL) positivity is frequently observed in hemodialysis (HD) patients and is associated with AVF thrombosis and stenosis. This study aimed to evaluate AVF stent survival without stenosis in aPL-positive hemodialysis patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A monocentric retrospective observational study was conducted on 35 patients who underwent AVF stenting between 1st January 2014 and 31st December 2023. The patients were divided into two groups: the aPL+ group [defined by a score of 3 or more based on the laboratory criteria of the 2023 ACR\/EULAR for antiphospholipid syndrome (APS)] and the control group. Intrastent restenosis was defined as a chronic change in the AVFphysical examination or blood flow, confirmed by ultrasound (US) or angiography. Kaplan\u2013Meier survival analysis was used to estimate the probability of stent survival without restenosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of intrastent restenosis was significantly higher in the aPL+ group at 24\u202fmonths. The Kaplan\u2013Meier survival analysis showed a significantly lower probability of AVF stent survival without restenosis in the aPL+ group (age-adjusted Hazard Ratio, 2.13 [IC95%, 1.70\u20132.69]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To the best of our knowledge, we describe for the first time a statistically significant association between aPL+ and AVF intrastent restenosis. Intimal hyperplasia is a non-thrombotic lesion associated with aPL+ and is linked to the mammalian target of rapamycin (mTOR) signaling pathway. We hypothesize that aPL may contribute to intrastent restenosis by inducing intimal hyperplasia. Whether this phenomenon is mTOR-mediated and whether sirolimus-eluting stents or balloons could be a better option for aPL+ patients requires further study.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1497810","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T06:46:55Z","timestamp":1735886815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiphospholipid antibodies positivity as a potential risk factor for restenosis following arteriovenous fistula stenting in hemodialysis patients: a pilot study"],"prefix":"10.3389","volume":"11","author":[{"given":"Maxime","family":"Taghavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Lengel\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleh","family":"Kaysi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Collart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Demulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Nortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2019.12.001","article-title":"KDOQI clinical practice guideline for vascular access: 2019 update","volume":"75","author":"Lok","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41581-020-0333-2","article-title":"Challenges and novel therapies for vascular access in haemodialysis","volume":"16","author":"Lawson","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamasurg.2021.4527","article-title":"Arteriovenous fistula maturation, functional patency, and intervention rates","volume":"156","author":"Huber","year":"2021","journal-title":"JAMA Surg"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1681\/ASN.2005050615","article-title":"Hemodialysis vascular access dysfunction","volume":"17","author":"Roy-Chaudhury","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000338347","article-title":"Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention","volume":"122","author":"Perl","year":"2012","journal-title":"Cardiology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3899\/jrheum.2022-1200","article-title":"Efforts to better characterize \u00ab an-tiphospholipid antibody nephropathy \u00bb for the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria: renal pathology subcommittee report","volume":"51","author":"Barbhaiya","year":"2024","journal-title":"J Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.3390\/jcm13144191","article-title":"Antiphospholipid syndrome: insights into molecular mechanisms and clinical manifestations","volume":"13","author":"Celia","year":"2024","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the an-tiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1053\/j.ajkd.2019.08.032","article-title":"mTORC pathway activation and effect of Sirolimus on native kidney antiphospholipid syndrome nephropathy: a case report","volume":"76","author":"Dufour","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib13010001","article-title":"Antiphospholipid antibodies associated with native arteriovenous fistula complications in hemodialysis patients: a comprehensive review of the literature","volume":"13","author":"Taghavi","year":"2024","journal-title":"Antibodies"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae308","article-title":"Antiphospholipid antibody positivity is associated with maturation failure and thrombosis of native arteriovenous fistula: a retrospective study in HD patients","volume":"17","author":"Taghavi","year":"2024","journal-title":"Clin Kidney J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hdi.12847","article-title":"Antiphospholipid antibodies in end-stage renal disease: a systematic review and meta-analysis","volume":"24","author":"Ames","year":"2020","journal-title":"Hemodial Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/ijms25031715","article-title":"Intrastent restenosis: a comprehensive review","volume":"25","author":"Bajeu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.ajkd.2020.11.022","article-title":"Efficacy and safety of paclitaxel-coated balloon angioplasty for dysfunctional arteriovenous fistulas: a\u202fmulticenter randomized controlled trial","volume":"78","author":"Yin","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.3390\/jcm11247405","article-title":"Angioplasty of dysfunctional dialysis fistula or graft with resveratrol-excipient and paclitaxel-coated balloon improves primary patency rates compared to plain angioplasty alone","volume":"11","author":"Novak","year":"2022","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.03.015","article-title":"Prospective, randomized, multicenter clinical study comparing a self-expanding covered stent to percutaneous transluminal angioplasty for treatment of upper extremity hemodialysis arteriovenous fistula stenosis","volume":"104","author":"Dolmatch","year":"2023","journal-title":"Kidney Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1186\/s13063-021-05920-3","article-title":"SIroliMus coated angioPlasty versus plain balloon angioplasty in the tREatment of dialySis acceSs dysfunctION (IMPRESSION): study protocol for a randomized controlled trial","volume":"22","author":"Pang","year":"2021","journal-title":"Trials"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/RHU.0000000000000409","article-title":"Stents coated with mammalian target of rapamycin inhibitors (mTOR) appear to be the best choice in patients with antiphospholipid syndrome and myocardial infarction","volume":"22","author":"Mora-Ram\u00edrez","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"102813","DOI":"10.1016\/j.jaut.2022.102813","article-title":"Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis","volume":"128","author":"Tektonidou","year":"2022","journal-title":"J Autoimmun"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1497810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T06:46:57Z","timestamp":1735886817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1497810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":20,"alternative-id":["10.3389\/fmed.2024.1497810"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1497810","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"article-number":"1497810"}}